Reaction
Vascular Pseudoaneurysm reporting signals
As of the last recalculation, Vascular Pseudoaneurysm appears in 1,723 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is PRASUGREL HYDROCHLORIDE (PRR 52.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Prasugrel Hydrochloride | 43 | 52.4 | 52.6 |
| Clopidogrel Bisulfate | 212 | 28.4 | 28.5 |
| Heparin Sodium | 28 | 25.0 | 25.0 |
| Clopidogrel | 291 | 21.1 | 21.2 |
| Apixaban | 91 | 17.3 | 17.3 |
| Alteplase | 21 | 17.1 | 17.1 |
| Valganciclovir Hydrochloride Powder, | 16 | 16.0 | 16.0 |
| Enoxaparin Sodium | 67 | 14.6 | 14.6 |
| Atovaquone | 9 | 13.6 | 13.6 |
| Ticagrelor | 29 | 11.2 | 11.2 |
| Warfarin | 109 | 11.0 | 11.0 |
| Valganciclovir | 17 | 11.0 | 11.0 |
| Valganciclovir Hydrochloride | 17 | 11.0 | 11.0 |
| Meropenem | 28 | 10.7 | 10.7 |
| Warfarin Sodium | 40 | 10.6 | 10.6 |
| Isoniazid | 13 | 9.8 | 9.8 |
| Tacrolimus Ointment 0.1% | 93 | 9.5 | 9.5 |
| Tacrolimus Extended-Release Capsules | 93 | 9.5 | 9.5 |
| Cefazolin Sodium | 9 | 9.1 | 9.1 |
| Rivaroxaban | 144 | 9.0 | 9.0 |
| Tacrolimus | 107 | 8.7 | 8.7 |
| Posaconazole Delayed-Release | 7 | 7.7 | 7.7 |
| Pravastatin Sodium | 12 | 7.4 | 7.4 |
| Durvalumab | 12 | 7.2 | 7.2 |
| Micafungin Sodium | 5 | 7.1 | 7.1 |
| Pitavastatin Calcium | 6 | 7.1 | 7.1 |
| Daptomycin | 5 | 6.6 | 6.6 |
| Bevacizumab | 60 | 6.0 | 6.0 |
| Amphetamine | 4 | 5.9 | 5.9 |
| Irinotecan Hydrochloride | 6 | 5.7 | 5.7 |
| Cisplatin | 34 | 5.3 | 5.3 |
| Obinutuzumab | 7 | 5.2 | 5.2 |
| Dabigatran Etexilate | 29 | 4.6 | 4.6 |
| Dabigatran Etexilate Mesylate | 25 | 4.2 | 4.2 |
| Alpelisib | 3 | 4.2 | 4.2 |
| Atezolizumab | 13 | 4.1 | 4.1 |
| Emicizumab | 3 | 2.9 | 2.9 |